TY - JOUR
T1 - An update on the efficacy of Venetoclax for chronic lymphocytic leukemia
AU - Lovell, Alexandra R.
AU - Sawyers, Jacki
AU - Bose, Prithviraj
N1 - Publisher Copyright:
© 2023 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Introduction: The BCL2 inhibitor venetoclax has dramatically changed the treatment of chronic lymphocytic leukemia (CLL) and has introduced the concept of time-limited therapy with targeted agents. Areas covered: This review discusses the mechanism of action of venetoclax, adverse effects, and the clinical data with this agent as identified by a selective search of clinical trials in the PubMed database. Venetoclax is FDA-approved with anti-CD20 monoclonal antibodies; however, research is ongoing evaluating its efficacy when given in combination with other agents, such as the Bruton’s Tyrosine Kinase (BTK) inhibitors. Expert opinion: Venetoclax-based therapy is an excellent treatment option for patients interested in time-limited therapy and can be offered in both the front-line and relapsed/refractory settings. Tumor lysis syndrome (TLS) risk evaluation, preventative measures, and strict monitoring should be conducted, while these patients ramp up to target dose. Venetoclax-based therapies produce deep and durable responses with patients often achieving undetectable measurable residual disease (uMRD). This has led to a discussion of MRD-driven, finite-duration treatment approaches, although longer term data is still needed. While many patients eventually lose uMRD status, re-treatment with venetoclax remains an area of interest with promising results. Mechanisms of resistance to venetoclax are being elucidated, and research is ongoing.
AB - Introduction: The BCL2 inhibitor venetoclax has dramatically changed the treatment of chronic lymphocytic leukemia (CLL) and has introduced the concept of time-limited therapy with targeted agents. Areas covered: This review discusses the mechanism of action of venetoclax, adverse effects, and the clinical data with this agent as identified by a selective search of clinical trials in the PubMed database. Venetoclax is FDA-approved with anti-CD20 monoclonal antibodies; however, research is ongoing evaluating its efficacy when given in combination with other agents, such as the Bruton’s Tyrosine Kinase (BTK) inhibitors. Expert opinion: Venetoclax-based therapy is an excellent treatment option for patients interested in time-limited therapy and can be offered in both the front-line and relapsed/refractory settings. Tumor lysis syndrome (TLS) risk evaluation, preventative measures, and strict monitoring should be conducted, while these patients ramp up to target dose. Venetoclax-based therapies produce deep and durable responses with patients often achieving undetectable measurable residual disease (uMRD). This has led to a discussion of MRD-driven, finite-duration treatment approaches, although longer term data is still needed. While many patients eventually lose uMRD status, re-treatment with venetoclax remains an area of interest with promising results. Mechanisms of resistance to venetoclax are being elucidated, and research is ongoing.
KW - anti-CD20 monoclonal antibodies
KW - BCL2 inhibitors
KW - Bruton‘s tyrosine kinase inhibitors
KW - Chronic lymphocytic leukemia
KW - Measurable residual disease
KW - Venetoclax
UR - http://www.scopus.com/inward/record.url?scp=85161057667&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85161057667&partnerID=8YFLogxK
U2 - 10.1080/14656566.2023.2218545
DO - 10.1080/14656566.2023.2218545
M3 - Review article
C2 - 37226798
AN - SCOPUS:85161057667
SN - 1465-6566
VL - 24
SP - 1307
EP - 1316
JO - Expert opinion on pharmacotherapy
JF - Expert opinion on pharmacotherapy
IS - 11
ER -